NCT06367205 Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations
| NCT ID | NCT06367205 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Delayed Graft Function |
| Study Type | INTERVENTIONAL |
| Enrollment | 380 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 380 participants in total. It began in 2024-03-01 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Delayed graft function (DGF), delineated by the necessity for dialytic intervention within the initial week post-transplantation, afflicts approximately 20%-50% of recipients. The primary objective of this study is to investigate the potential efficacy of norepinephrine infusion in conjunction with goal-directed fluid therapy (GDFT) in mitigating the occurrence of DGF among individuals undergoing kidney transplantations. The findings of this investigation have the potential to advance the field of perioperative care in kidney transplantations by providing insights into optimized management strategies.
Eligibility Criteria
Inclusion Criteria: 1. Recipients aged 18 years or older 2. Scheduled to undergo kidney transplantations under general anesthesia 3. Cadaveric kidney transplantations 4. Sign the informed consent form Exclusion Criteria: 1. Donors aged under 18 years 2. Donor kidneys classified as Maastricht category I or II 3. Contraindications to radial artery catheterization 4. Pregnancy 5. Cardiac dysfunction (exercise tolerance less than 4 METS) 6. Severe liver dysfunction (Child Pugh C-grade) 7. Respiratory diseases with tidal volume intolerance exceeding 8ml/kg 8. Severe arrhythmias, including atrial fibrillation, frequent atrial or ventricular premature beats, moderate or severe aortic and mitral regurgitation 9. Double-kidney transplantations 10. Simultaneous organ or additional surgeries during kidney transplantations 11. Repeat kidney transplantations 12. Concurrent participation in other clinical trials 13. Patients deemed ineligible by researchers
Contact & Investigator
Diansan Su, Dr.
PRINCIPAL INVESTIGATOR
Department of Anesthesiology Renji Hospital
Frequently Asked Questions
Who can join the NCT06367205 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Delayed Graft Function. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06367205 currently recruiting?
Yes, NCT06367205 is actively recruiting participants. Contact the research team at diansansu@yahoo.com for enrollment information.
Where is the NCT06367205 trial being conducted?
This trial is being conducted at Zhengzhou, China, Shenyang, China, Shanghai, China.
Who is sponsoring the NCT06367205 clinical trial?
NCT06367205 is sponsored by RenJi Hospital. The principal investigator is Diansan Su, Dr. at Department of Anesthesiology Renji Hospital. The trial plans to enroll 380 participants.